Welcome to our dedicated page for Quantum Biopharma Ltd. Class B Subordinate Voting Shares news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum Biopharma Ltd. Class B Subordinate Voting Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quantum Biopharma Ltd. Class B Subordinate Voting Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quantum Biopharma Ltd. Class B Subordinate Voting Shares's position in the market.
Quantum BioPharma (NASDAQ:QNTM) announces the commencement of sentinel dosing for its Phase 1 multiple ascending dose clinical trial of Lucid-21-302 in Australia. The study aims to evaluate the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants, marking a significant step toward Phase 2 efficacy trials for multiple sclerosis treatment. The company has also retained several firms for market awareness and investor relations, including Agoracom ($25,000 CAD), Independent Trading Group ($7,500 CAD monthly), Buyins ($15,000 USD), and Stockjock ($15,000 USD).
Quantum Biopharma (Nasdaq: QNTM) has filed a market manipulation lawsuit against CIBC World Markets and RBC Dominion Securities. The complaint alleges that defendants engaged in 'spoofing' - placing sell orders they didn't intend to fill - to artificially lower the stock price over a four-year period. This manipulation allegedly occurred more than a thousand times, causing significant harm to both the company and shareholders. Quantum Biopharma claims it was forced to sell shares at artificially depressed prices during this period and is now seeking damages to compensate for losses.
Quantum BioPharma (NASDAQ:QNTM) has filed a complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets, RBC Dominion Securities, and others. The lawsuit alleges that between January 1, 2020, and August 15, 2024, the defendants engaged in market manipulation through "spoofing" techniques, violating securities laws. Quantum BioPharma is seeking damages exceeding $700 million USD.
The company has posted a copy of the complaint on its website for public access. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The complaint alleges that the defendants' actions artificially depressed Quantum BioPharma's stock price, harming both the company and its retail investors.
Quantum BioPharma's stock price has fallen from over $460 USD per share in January 2020 to $7.55 USD as of October 18, 2024, reducing its market cap from nearly $1 billion to less than $15 million. The company believes other banks/brokers may be involved in the alleged manipulation but has not named them at this time.
Quantum BioPharma (NASDAQ: QNTM) has filed a US federal lawsuit against CIBC World Markets, RBC Dominion Securities, and others, seeking damages exceeding $700 million USD for alleged stock price manipulation through spoofing. The lawsuit, filed on October 20, 2024, in the Southern District of New York, claims violations of the Securities Exchange Act of 1934 between January 1, 2020, and August 15, 2024.
The company alleges that the defendants used spoofing techniques to artificially depress Quantum BioPharma's stock price. In January 2020, the stock traded over $460 USD per share with a market cap near $1 billion, but as of October 18, 2024, it closed at $7.55 USD per share with a market cap under $15 million.
Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The company remains open to dialogue for an amicable solution with the involved banks and brokers.
Quantum BioPharma (NASDAQ:QNTM) has filed a $700 million USD lawsuit against CIBC World Markets, RBC Dominion Securities, and others in the US District Court for the Southern District of New York. The lawsuit alleges market manipulation through 'spoofing' techniques between January 1, 2020, and August 15, 2024, violating securities laws.
The company claims the defendants manipulated QNTM's stock price, causing significant harm to shareholders. Quantum's stock price fell from over $460 USD in January 2020 to $7.55 USD on October 18, 2024, reducing its market cap from nearly $1 billion to less than $15 million.
Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The company remains open to dialogue for an amicable solution with the involved parties.
Quantum BioPharma (NASDAQ: QNTM) has provided an update on Celly Nutrition Corp.'s signing of a Master Distribution Agreement with FUSION Distribution Group. This agreement covers Puerto Rico, The Caribbean, and parts of Central and South America. Celly Nutrition is launching unbuzzd™, an innovative beverage designed to support alcohol metabolism and promote alertness.
The partnership with FUSION, a leading brand incubator and distributor in the region, will introduce unbuzzd™ to new markets. The product is available on Amazon in Ready-to-Mix (RTM) powder sticks, with Ready-to-Drink (RTD) cans coming soon. FUSION's distribution network includes major retailers like Walmart, Walgreens, CVS, and Costco.
Celly Nutrition's CEO, John Duffy, formerly of Coca-Cola, and co-chair Gerry David, ex-CEO of Celsius Holdings, view this partnership as a significant opportunity for expansion in key vacation destinations where alcohol consumption is common.
Quantum BioPharma (NASDAQ:QNTM) has provided an update on Celly Nutrition Corp.'s recent developments. Celly Nu, led by former Coca-Cola executive John Duffy and co-chaired by ex-Celsius Holdings CEO Gerry David, has signed a master distribution agreement with FUSION Distribution Group. This partnership will introduce unbuzzd™, Celly Nu's innovative alcohol metabolism supplement, to Puerto Rico, the Caribbean, and parts of Central and South America.
unbuzzd™ is a scientifically formulated beverage product designed to support the body's natural processes for metabolizing alcohol and promoting alertness. It's currently available on Amazon as Ready-to-Mix (RTM) powder sticks, with Ready-to-Drink (RTD) cans coming soon. The partnership with FUSION, a leading brand incubator and distributor in the region, will expand unbuzzd's market presence through major retailers including Walmart, Walgreens, CVS, and Costco.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), a biopharmaceutical company focused on innovative assets and biotech solutions, has announced its participation in the ArcStone-Kingswood Growth Summit on September 26, 2024, in Toronto, ON. Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the event, which features over 30 public and private companies and 47 sponsors from around the world.
The presentation is scheduled for 2:45 p.m. to 2:55 p.m., followed by a 2-minute Q&A session. Mr. Sawyer will discuss the company's growth potential and connect with key investors. The summit aims to create meaningful public companies that drive value for both management and investors. It will be held at the Sheraton Hotel in downtown Toronto.
Quantum BioPharma (NASDAQ: QNTM) has closed a non-brokered private placement, issuing 6 Class A multiple voting shares at $6.00 each for gross proceeds of $36.00. The offering involved related-party transactions with insiders Xorax Family Trust and Fortius Research and Trading Corp. Following the offering, Xorax now owns 50% of outstanding Class A Shares and 34.28% of voting rights, while Fortius owns 50% of outstanding Class A Shares and 34.06% of voting rights. The company plans to use the proceeds for general working capital purposes. The transaction was exempt from formal valuation and minority shareholder approval requirements under MI 61-101.
Quantum BioPharma (NASDAQ:QNTM) has signed an agreement with Ingenu CRO Pty to conduct a clinical study observing disease progression in patients with primary progressive multiple sclerosis. The study, announced on September 9, 2024, will be carried out through Quantum's subsidiary, HUGE Biopharma Australia Pty This observational study is a important step towards initiating a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS), advancing Quantum's multiple sclerosis research program. Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at Quantum Biopharma, expressed enthusiasm about the collaboration, highlighting its importance in progressing their MS research efforts.
FAQ
What is the current stock price of Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)?
What is the market cap of Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)?
